Source: Virtual Congress 2020 – Pharmacological management of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Ismaila (Collegeville, United States of America), R. Wood ( Bollington, United Kingdom), G. Anley (Brentford, United Kingdom), Y. Nam ( Bollington, United Kingdom), D. Bluff ( Bollington, United Kingdom), L. Sansbury (Collegeville, United States of America). Economic impact of delayed multiple-inhaler triple therapy initiation in COPD patients. 2426

Member's Comments

No comment yet.

Related content which might interest you: Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 Symptomatic burden of COPD for patients receiving dual or triple therapy Source: International Congress 2017 – Management of COPD Year: 2017 Cost burden in COPD patients initiating ICS vs. non-ICS maintenance regimens Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019 Resource utilization and economic impact of switching uncontrolled asthma and exacerbating COPD patients on monotherapy to fixed dose combination treatment in Germany Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline Source: International Congress 2018 – COPD management Year: 2018 Comparison of initial drug treatment of incident COPD patients with German treatment guidelines Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 The psychological status of COPD patients: the impact of the long-term complex treatment and pulmonary rehabilitation Source: Eur Respir J 2003; 22: Suppl. 45, 53s Year: 2003 Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses Source: International Congress 2017 – COPD management Year: 2017 Preventing clinically important deterioration with single-inhaler triple therapy in COPD Source: ERJ Open Res, 4 (4) 00047-2018; 10.1183/23120541.00047-2018 Year: 2018 Does short-term treatment intensification influence long-term treatment effects on health status in COPD? Source: Eur Respir J 2005; 26: Suppl. 49, 293s Year: 2005 The influence of fenspiride in complex therapy on quality of life in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010 The role of biomarkers and effectiveness of maintenance therapy in stable severe COPD Source: International Congress 2017 – COPD management Year: 2017 Effect of bronchodilator therapy on the quality of life of pulmonary TB patients Source: Eur Respir J 2002; 20: Suppl. 38, 442s Year: 2002 Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002 Cost impact of time to initiation of triple therapy in COPD patients in Japan: A retrospective analysis of healthcare claims data Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Influence of statin therapy on exacerbation frequency in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009